Oncology
🇪🇺 EMA Page 7EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 73–84 of 94 articles
EU BioPharma Clinical Trials: Key Oncology Data at ASCO & AUA
Kelun-Biotech's Sac-TMT Cancer Drug Selected for Three ASCO 2026 Oral Presentations
Allogene Therapeutics Expands Cemacabtagene Ansegedleucel Phase 2 ALPHA3 Trial to South Korea and Australia
Biocon Receives Health Canada Approval for Denosumab Biosimilars Bosaya and Vevzuo
EGFR Inhibitors Market Access in Europe: Launch Strategies & Challenges
NICE Technology Appraisals & G-BA Assessments for EMA-Approved Oncology Drugs 2026
PRAC Safety Signal Assessment: Insights on Bispecific Antibodies in Hematologic Malignancies
BriaCell Bria-OTS+ Shows Preserved Quality of Life in Phase 3 Metastatic Breast Cancer Trial at AACR 2026
EMA Accelerated Assessment Program: Impact on Oncology Drug Approval Timelines
EMA Conditional Approval Pathway: Linvoseltamab and Oncology Access in EU
CAR-T Therapies Cost-Effectiveness: EU HTA Bodies' Divergent Assessments
Real-World Evidence EU Drug Development: EMA's Hybrid Trial Framework